Conference Information

Welcome Message

Welcome you the "9th International Conference on Parkinson’s and Movement Disorders,” which will take place in Vienna, Austria, on October 02-04, 2023. This year's conference, with its novel theme "Recent Research Methods and Findings in Parkinsons and Movement Disorders," will benefit a wide range of specialists in the disciplines of neuroscience, neurology, and neurosurgery.

The attendees will get a great opportunity to network with top professionals, scientists, physicians, and researchers. Leading researchers in this interesting topic, as well as business executives and investors, will be able to share ideas at this conference. Moreover, this conference is a valuable experience for learning about the fields of neurology, Parkinson's disease, and movement disorders.

This year's conference assure to be an exceptional one, featuring keynote lectures, workshops, poster sessions. Our program covers a wide range of topics, including clinical research, neuroscience, and therapeutic approaches for Parkinson's and other movement disorders

We guarantee that Parkinson's Congress 2023 will be a huge part of your research, Come with us to make" 9^th International conference on Parkinson’s and movement disorders "a memorable event!

Session and Tracks

Session 1: Parkinsons Disease

A prevalent neurodegenerative condition known as Parkinson's disease (PD) is characterised by a movement disorders with bradykinesia, rest tremor, stiffness, and postural instability. There are few choices for treating Parkinson's disease (PD), and the majority of current methods are predicated on restoring striatal dopaminergic tone. They, however, do not change the course of the illness and do not address the non-dopamine-dependent Parkinson's symptoms of disease, which frequently have the most negative effects on quality of life.

The symptoms, the scant research being done to find symptomatic treatment for non-motor Parkinson’s disease symptoms, and the development and clinical testing of drugs that show promise for disease modification in Parkinson’s disease that is already manifest. A methodological challenge that must be overcome in the future is the lack of agreement on primary endpoints for clinical trials that reflect the progression in prodromal stages of Parkinson’s disease, such as rapid eye movement sleep behaviour disorder (RBD), which is one reason why prevention (i.e., slowing or stopping Parkinson’s disease in a prodromal stage) is still a pipe dream.

Related Association and Societies:

Parkinson foundation | American Parkinson Disease Association | Movement Disorders Society of Japan | Movement disorders – Swiss Society of Young Neurologists | UK Parkinson’s Action Network | American Academy of Neurology, Movement Disorders Society | European Neurological Society Asian and Oceanian Parkinson's Disease and Movement Disorders | Parkinson's Disease and Movement Disorders association | Movement Disorders Society of India | Parkinson Society Canada, Michael J. Fox Foundation, Parkinson Association of the Carolinas, Parkinson’s NSW | Parkinson’s Unity Walk | American Parkinson Disease Association

Associated Journals:

Related Conferences:

Session 2: Movement disorder

Many movement disorders can be caused by a wide and expanding number of drugs. Drug-induced movement disorders are incapacitating, although they are frequently treated ineffectively and with little recognition. Second generation antipsychotic drugs in particular, like first generation drugs, are linked to potentially crippling adverse effects, most notably tardive syndromes and parkinsonism, as well as possibly lethal acute syndromes.

As more patients, especially children and the elderly, who are susceptible to these side effects are taken these medications, appropriate, evidence-based care is crucial. When prescribing drugs that might cause movement disorders, prevention of the onset of these illnesses is a crucial factor to take into account. The approval of valbenazine and deutetrabenazine, the first medications prescribed for the diagnosis and treatment of drug-induced Parkinson’s disease and dopamine transporter imaging, respectively

Related Association and Societies:

American Parkinson Disease Association | International conference on Parkinson’s and movement disorders society | American Parkinson's Disease Association | Movement Disorders Society of India | Asian and Oceanian Parkinson's Disease and Movement disorders | Parkinson's Disease and Movement Disorders association | Movement disorders – Swiss Society of Young Neurologists | Movement Disorder Society of Japan | Parkinson Association of the Carolinas, Parkinson’s NSW | Parkinson's foundation | Parkinson’s Unity Walk

Associated Journals:

Related Conferences:

Session 3: Parkinson's psychosis

Parkinson's disease (PD) is a neurological condition that affects older persons more frequently than Alzheimer's disease, and its incidence is rising globally. Parkinson's disease psychosis (PDP) is a frequent, non-motor symptom of Parkinson disease that adds to carer stress and raises the likelihood that a patient may be sent to a nursing home. The epidemiology, characteristics, diagnosis, and therapy of Parkinson's disease psychosis is discussed in this work. Parkinson’s disease psychosis often manifests as a progression of modest, then progressively sophisticated visual hallucinations, which are mediated by dopaminergic-serotonergic interactions activating the mesolimbic pathway with support from additional brain structures and neurotransmitters.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 4: Neurology

The use of electromagnetic imaging for the diagnosis and treatment of brain damage and other neurological conditions, including Parkinson's disease and movement disorders, we’ll combine the most recent developments in electromagnetic imaging techniques.

Animal research, and human experimental investigations for applications including brain damage, Parkinson's disease, and other neurological disorders like movement disorders. research on electromagnetic imaging techniques geared towards epilepsy or other neurological disorders; research on the application of electromagnetic imaging in fast neural imaging; the study of the bio-electromagnetic properties of brain tissue; and electromagnetic imaging algorithms and experimental studies for rapid brain injury detection.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 5: Device Strategies in Advanced Parkinson’s Disease Treatment

Most individuals receiving peroral levodopa have motor fluctuations and dyskinesia within the first few years of medication. Deep brain stimulation (DBS), levodopa-carbidopa intestinal gel infusion (LCIG), and subcutaneous infusion of the dopamine agonist apomorphine are examples of device-aided Parkinson’s disease (PD) therapy that are helpful at reducing dyskinesia and motor fluctuations. The "time with Parkinson’s disease symptoms (off time)" appears to be reduced by at least 60%–65% with the use of these three therapeutic approaches.

The usage of cutting-edge treatment also significantly lowers dyskinesia. Current research suggests that these treatments can help a variety of nonmotor symptoms in advanced Parkinson's disease. In the majority of treated patients, this results in an improvement in health-related quality of life. This improves the quality of life connected to health in the vast majority of treated individuals.

Serious side effects of DBS include infection and cerebral haemorrhage. For LCIG, complications relate to the infusion equipment and the creation of the percutaneous endoscopic gastrostomy.

For apomorphine infusion, the most frequent side effect is the development of noduli (local inflammation) at the point of infusion. When oral or transdermal Parkinson’s disease medicines cannot be further adjusted, device-aided treatments are all recommended for the treatment of motor fluctuations and/or dyskinesia. However, the selection of device-assisted therapy is based not only on indications and contraindications but also on the symptom profile and personal preferences of the patient.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 6: Stroke

Parkinson's disease and Parkinsonism are both conditions that affect movement. Vascular Parkinson’s is the medical term for a stroke that affects the substantia nigra or basal ganglia. Similar to previous strokes, the loss of blood flow to specific parts of the brain is the main factor in the damage.

Parkinson’s-related strokes are known as small vessel strokes since they often don't have life-threatening consequences.
Typically, it takes a number of little strokes before vascular Parkinson’s symptoms appear.
Brain scans like a CT or MRI can be used to confirm the diagnosis of small vessel strokes in Parkinson’s disease patient

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 7: Development in Drugs for Shaking palsy

Parkinson's disease (PD) is a neurological condition that worsens with time and generally affects older adults. It is a major cause of disability globally. Importantly, the creation of intracellular inclusion bodies containing misfolded -synuclein protein aggregates and nigrostriatal loss are the neuropathological hallmarks of Parkinson's disease.

Dopaminergic medication can be used for years after the beginning of the symptoms to effectively address cardinal motor symptoms such tremor, rigidity, and bradykinesia. Nevertheless, individuals eventually have symptoms that are no longer completely responsive to dopaminergic therapy.

Targeting the most notable pathological hallmark of Parkinson's disease, -synuclein accumulation, as well as other molecular pathways that contribute to the pathophysiology of Parkinson disease, translational molecular imaging concepts have become more and more supportive of efforts to find disease-modifying drugs. In fact, molecular imaging techniques like positron emission tomography (PET) and single-photon.

Related Association and Societies:

Medical Society of Parkinson movement disorder London in 1787 | Movement Disorder Society of Japan | American Parkinson's Disease Association | Regenerative therapy congress |Asian and Oceanian Parkinson's Disease and Movement disorders | Management of Psychosis in Parkinson's Disease | Movement Disorders Society of India | Parkinson’s Unity Walk | Parkinson Association of the Carolinas, Parkinson’s NSW | Movement Disorders Society of India | Parkinson's Foundation Association of Physiotherapists in Parkinson’s

Associated Journals:

Related Conferences:

Session 8: Neurodegenerative diseases in Parkinsons

Model disorders include Parkinson's illness and Huntington's illness. Huntington's disease is just one of a rising number of trinucleotides repeat illnesses, while Parkinson's disease is the most prevalent of multiple akinetic-rigid syndromes.There is now genuine hope for Parkinson’s disease-modifying therapy in the not-too-distant future for patients with Parkinson's disease or Huntington's disease and movement disorders thanks to molecular genetic studies and subsequent molecular biological studies that have revealed fascinating new insights into the pathogenesis of both disorders.

Related Association and Societies:

Parkinson’s Unity Walk | Parkinson Association of the Carolinas, Parkinson’s NSW Regenerative therapy congress | Neurological and stroke disorder association | Association of Physiotherapists in Parkinson’s | Movement Disorders Society of India | Movement Disorders Society of India | Asian and Oceanian Parkinson's Disease and Movement disorders | Movement Disorder Society of Japan | American Parkinson's Disease Association | Parkinson's Foundation

Associated Journals:

Related Conferences:

Session 9: Neuroanatomy and neuropathology

Parkinson's disease (PD) cognitive impairment is caused by complicated, poorly understood pathophysiological alterations. Hence, it is crucial to recognise the structural alterations causing cognitive deterioration in Parkinson's disease early enough in order to provide effective therapy. In this review, we talk about how Parkinson's disease affects the primary cognitive brain areas in terms of neuroanatomical alterations.

To give current knowledge for a better understanding of the biology of Parkinson's disease, which will aid researchers and clinicians in planning and developing innovative treatment approaches for the benefit of PD patients, we have incorporated the important findings of several studies.

Bradykinesia (bradykinesia), stiffness, postural instability, and tremor are all symptoms of Parkinson's disease (PD).

This condition can result from a number of pathologic processes, but neurodegeneration coupled with Lewy body-like inclusions in the neurons is thought to be the usual pathologic correlate of Parkinson's disease.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 10: Treatment of Parkinson’s and Alzheimer’s Disease

The two most typical neurodegenerative illnesses seen in clinical practise are Alzheimer's disease (AD) and Parkinson's disease (PD). While dementia has long been associated with AD, it is increasingly recognised as a component of the clinical spectrum in Parkinson’s disease (PDD). In individuals with AD and Parkinson’s disease, cognitive dysfunctions and neuropsychiatric consequences, including as psychosis, mood and anxiety disorders, and sleep disturbances, commonly coexist. The prevalence of such symptoms can exacerbate pre-existing cognitive deficiencies and is frequently a substantial source of disability. Pharmacological and non-pharmacological interventions are used to treat AD and Parkinson’s disease. Although there has been considerable progress in pharmaceutical therapy for AD and Parkinson’s disease in terms of creating symptomatic remedies, the advantages are frequently modest and short-lived. Due to these drawbacks, researchers are looking at cutting-edge, non-pharmacological therapies for both AD and Parkinson’s disease. In addition, given the wide range of additional neuropsychiatric, physical, and behavioural symptoms that frequently accompany AD and Parkinson’s disease, it is important to take into account any possible adverse effects of pharmaceutical treatments, as improving one symptom may make others worse, making clinical management of these patients challenging.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 11: Neuroimaging

The use of neuroimaging to evaluate movement disorders therapy choices, specifically for Parkinson's disease (PD). Recently, imaging techniques have been used in studies of prospective neuroprotective drugs to evaluate dopaminergic function. To measure the alteration of network activity as an objective marker of the treatment response, new imaging techniques that use regional metabolism and/or cerebral perfusion have recently been developed. Both imaging techniques have offered fresh insights into the workings of various pharmaceutical and stereotactic surgical approaches to the treatment of Parkinson's disease and other movement disorders.

This comprehensive review sought to: (1) identify the brain areas associated with anxiety in Parkinson's disease (PD) based on neuroimaging studies; and (2) interpret the results in light of the malfunctioning of the limbic cortico-striato-thalamocortical circuit and fear circuit.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 12: Neuro muscular disorders

Manifested forward flexion of the trunk, also known as camptocormia, is a common sign of Parkinson's disease.

Paraspinal muscles were examined in four camptocormic Parkinson's patients using electromyography (EMG), axial computed tomography (CT), or magnetic resonance imaging (MRI), as well as muscle biopsy. Many fibrillations, positive sharp waves, and strange high-frequency discharges were visible on the EMG of the lumbar and thoracic paravertebral muscles.

The paraspinal muscles were biopsied, and the results showed mitochondrial myopathy, chronic inflammatory myopathy, unspecific myopathic alterations, or end-stage myopathy with autophagic vacuoles. Parkinson's and movement disorders patients with considerable trunk forward flexion should be evaluated for myopathy restricted to the erector spinae muscles.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 13: Novel therapeutics

The movement condition with the highest prevalence in the world is Parkinson's disease (PD). Dopaminergic neuron loss and the development of Lewy bodies are the main pathological indicators of Parkinson's disease. There is currently no therapy for Parkinson's disease; only symptomatic measures are used. To stop the progression of neurodegeneration, researchers are looking for neuroprotective drugs and disease-modifying techniques. Several therapeutic targets, however, fell short of providing neuroprotective benefits in human studies because to a paucity of information on the primary pathogenic process of Parkinson disease. Current research points to the C-Abelson (c-Abl) tyrosine kinase enzyme's role in the aetiology of Parkinson's disease.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 14: Deep brain stimulation

Deep brain stimulation (DBS) is an electrical device that is implanted and modifies specific brain targets to alleviate symptoms of a certain neurologic condition, most frequently a movement disorders.

When medicinal therapy for essential tremor, Parkinson's disease, and dystonia becomes unsuccessful, unbearable due to side effects, or creates motor difficulties, it is frequently utilised.

Implanted brain targets now include the globus pallidus (Parkinson's disease and dystonia), subthalamic nucleus (most usually for Parkinson's disease), and the thalamus (most frequently for essential tremor). Other targets are actively being investigated. Future innovations might include brain electrodes with the ability to direct current and "closed loop" stimulation devices, which can record and decipher regional brain activity and adjust stimulation settings in a therapeutically relevant manner. The use of brand-new image-guided insertion methods may be superior than conventional DBS surgery.

Related Association and Societies:

Associated Journals:

Related Conferences:

Session 15: Clinical trials in neurology

Parkinson’sdisease clinical trials enrolment, summarize recently proposed and tested interventions, and propose next steps to increase equity and representation in Parkinson’s disease research. Clinical trials in Parkinson's disease is susceptible to upstream biases and disparities, from Parkinson’s disease awareness to access to specialist Parkinson’s disease facilities. While more Parkinson’s disease research is still required, recent studies have identified some potential approaches for boosting the recruitment of underrepresented minorities (URMs), such as expanding the accessibility of linguistically and culturally diverse research materials and team members, collaborating with neighbourhood organisations, and developing connections with community physicians who serve URMs.

Related Association and Societies:

Associated Journals:

Related Conferences

Session 16: Clinical trials in Parkinson's and movement disorders

The effects of the COVID-19 pandemic, not only for people with mobility impairments but for everyone on the planet. Studies looking into how COVID-19 affected people with Parkinson's disease have suggested that Parkinson’s symptoms worsened in those who were infected, that people with more advanced Parkinson's disease were at an increased risk of pulmonary compromise, that people with Parkinson's disease who were hospitalised and had COVID-19 appeared to have a higher mortality rate, and that people with Parkinson's disease displayed more stress, depressive symptoms, and anxiety.

An enhanced awareness of this possible correlation as well as its underlying biological mechanisms has resulted from a case report associating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with new-onset Parkinson's disease.

Related Association and Societies:

Associated Journals:

Related Conferences:

Market Analysis

Parkinson's Disease Drugs Market Research, 2031

In 2021, the market for medications for Parkinson's disease was estimated to be worth $5.7 billion. By 2031, it is expected to have grown to $10.4 billion, with a CAGR of 6.2% between 2022 and 2031. Parkinson's disease is a neurological condition commonly known as idiopathic Parkinsonism. It is a chronic disorder that affects both the neurological system and the parts of the body that the nervous system regulates. The substantia nigra is a part of the brain where dopamine is made. Parkinson's disease causes the substantia cells in the brain to start dying, which lowers the level of dopamine in the body.

The global Parkinson’s disease drugs market also declined in 2020 due to global economic recession led by COVID-19. However, market witness recovery in the year 2021, owing to increase in adoption of Parkinson’s disease drugs and rise in R&D pipeline products of Parkinson’s disease drugs.

Parkinson's disease may be brought on by environmental and hereditary factors. Given that some genes are known to be significant risk factors for the disease, those who have a family member who has the condition are at an elevated chance of developing it themselves. Tremor, sluggish movement, tight muscles, poor posture, unsteadiness, changes in speech, etc. are some of the warning signs and symptoms. Typically, symptoms appear gradually, and as the condition progresses, non-motor symptoms increase in frequency. Age and other factors including the environment and heredity are the main risk factors.

Over the projection period, there will likely be a rise in demand for Parkinson's disease medications due to an ageing population that fuels the market's expansion. The business for Parkinson's disease pharmaceuticals is also growing as a result of key companies increasing their spending in R&D for Parkinson's disease drugs and an increase in the population of older people. The market expansion, however, can be constrained by adverse reactions to medications for Parkinson's disease. On the other hand, important firms may anticipate to benefit from a profitable market opportunity for Parkinson's disease treatments due to the high growth potential in underdeveloped emerging nations and the expansion of R&D pipeline goods.

The market for medications for Parkinson's disease is divided into segments based on drug class, method of administration, age group, and geography. The market is divided into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors, and others based on the pharmacological class. It is divided into oral, injectable, and transdermal delivery methods based on the mode of administration. It is divided into two categories based on age range: 50 or under and above 50. Moreover, the market is examined throughout North America, Europe, Asia-Pacific, and LAMEA.

COVID-19 Impact Analysis

The COVID-19 pandemic has curtailed the movement of people, goods, and services worldwide, disrupted supply chains, restricted sales operations, marketing efforts, and customer field support, and impeded the shipping and delivery of products to customers. As a result, many companies experienced a decline in the sales of their revenue in 2020. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious disease has become a pressing medical issue worldwide. In addition to the development of vaccine and therapeutics drugs, COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Moreover, decrease in sales of Parkinson’s disease drugs and less hospital visits of Parkinson’s disease patients during pandemic negatively impacted the growth of Parkinson's disease drugs industry in 2020. However, the market is anticipated to witness recovery in 2021, and show stable growth during Parkinson's and movement disorders disease drugs market forecast.

Global Parkinson’s Disease Market by Drug Class

By drug class, the Parkinson’s and other movement disorders disease drugs market are divided into decarboxylase inhibitors, dopamine agonist, COMT inhibitors, MAO-B inhibitors and others. The decarboxylase inhibitors segment accounted for the largest Parkinson’s disease drugs market share in 2021, and is projected to grow at a CAGR of 6.2% during the forecast period owing to the rise in the prevalence of Parkinson’s disease and development associated with decarboxylase inhibitors are. On the other side, COMT inhibitor expected to register for the fastest growth rate during the forecast period owing to advantages associated with COMT inhibitors such as long-lasting enzyme inhibition, reduces the adverse effects of drugs and less levodopa dose.

Parkinson's Disease Drugs Market

The decarboxylase inhibitors held largest share in the global market in 2021.

Parkinson's disease medication sales worldwide, by route of administration

The Parkinson's medicine market is divided into oral, injectable, and transdermal dosage forms based on the method of delivery. Due to the more predetermined dosages, simplicity, and patient self-administration, the oral category, which contributed the majority of revenue in 2021, is predicted to expand at the quickest rate throughout the projection period.

Parkinson's Disease Drugs Market

By Route Of Administration

In 2021, the oral segment had the biggest market share, and it is anticipated that it would continue to rule throughout the forecast period

Age-Group-Based Market for Parkinson's Disease Medications

Parkinson's disease medications are sold to people 50 years of age and older, according to age group. In 2021, the market was dominated by consumers over 50; over the projected period, it is expected that this trend would hold true. Because age is a risk factor for Parkinson's disease, the over-50 demographic segment is amplified as a result of an ageing population.

Market for Parkinson's Disease Medications Worldwide, by Region

The Parkinson's and movement disorders disease medicine market is examined by region, including North America, Asia-Pacific, Europe, and LAMEA. In 2021, North America held the largest market share for Parkinson's disease medications, and it is projected that this trend would continue during the forecast period. This is linked to elements including the presence of important players in the area, the accessibility of diagnostic facilities, and the expertise of neurologists. Also, the United States' excellent healthcare system is predicted to boost market expansion in North America.

The greatest CAGR is anticipated to be recorded over the projection period in Asia Pacific. This is attributable to the availability of services for Parkinson's disease patients and the presence of qualified neurologists, which are the main driving forces behind the market growth for movement disorders disease pharmaceuticals in the area.

The major companies profiled in the report include AbbVie Inc., Gentech Healthcare, Amneal Pharmaceuticals Inc Cantata Bio, Limited, Orion Corporation, Square group, Bio, Biogen Inc., C.H. Boehringer Sohn Ko.KG, Glaxosmithkline Plc, Intas Pharmaceuticals Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Torrent Group, Viatris Inc, Square group.

About Conference

We are excited to invite you all to Parkinson's congress 2023!

The "9th International Conference on Parkinson's and movement disorders" will be held in Vienna, Austria, from Oct 02-04, 2023.

We are extremely proud of this recognised international event and are glad to welcome all participants.

Parkinson's congress 2023 invites attendees from the world's finest academic institutions and clinical research facilities to contribute their work on all parts of this rapidly developing field, network with leading experts, and showcase cutting-edge techniques. This conference will improve the chance for specialists from across the world to engage scientifically and will to focus particularly on the current and interesting developments in Parkinson's research. Parkinson's congress 2023 is a yearly meeting of neurologists, neurosurgeons, psychiatrists, and research scholars to communicate how to collaborate and organise for the treatment of neurological illnesses.

Why to attend

With the help of Parkinson's panels, affiliations, and excellent presentations from neurologists, we work hard to make the"9th International Conference on Parkinson's and Movement Disorders", a huge success.

One of the largest international gathering of people with Parkinson's and movement disorders, this yearly conference provides a special chance to network with peers and gain knowledge from the top researchers in the field. You are likely to find something of interest at the conference, which has a wide range of talks on various issues relating to Parkinson's and movement disorders.

Benefits of Attending:

Keeping up to date with the latest research: Provides an opportunity to learn about the latest research findings and developments in the field. You can attend lectures and presentations by leading researchers, and gain insights into the latest advances in Parkinson's and movement disorders.

Networking: Brings together researchers, healthcare professionals, patients, and caregivers from around the world. Attending a conference can provide an opportunity to meet new people, form new connections, and build professional relationships. You may also be able to connect with potential collaborators or mentors.

Access to resources: Provides access to a range of resources, such as educational materials, research posters, and exhibitor booths showcasing the latest treatments and therapies.

Support: Provides a sense of community and support, particularly for individuals living with Parkinson's or movement disorders and their caregivers. You can connect with others who understand your experiences and share your challenges.

• Keynote addresses by the top experts in the field of neurology research

• Create connections with your peers and share insightful knowledge that will benefit in your success

• How to select and manage your academic course of study for success and individual gain

• Get knowledge about the current state of your profession

• Symposia and Workshops are expected to be impressed by Top Industry Representation

Target Audience

Neurologists
Neurosurgeons
Psychiatrists and academics
Gastroenterologist
The Student Delegates
Speech and / or occupational therapist
Parkinson's Research Directors
Doctors
Integrated Health Physicians
Psychologists/Psychotherapists
An occupational therapist
The Student Delegates
specialists in neurosurgery
Professors at universities and medical students
Industrial specialists
professionals working in neurology
Chiropractic specialists
Therapists for movement disorders and massage

Past Conference Report

The 11th International Conference on Parkinson's and Movement Disorders conducted as a virtual conference on December 9–10, 2022.

We want to start by expressing our pleasure for your participation in Parkinsons 2022, an international platform for delving into several significant parts of neurology and neuroscience. There are several ways we may express our gratitude to you for providing a great venue for the Parkinsons 2022 virtual meeting.

The gathering was notable for the participation of young, creative scientists, business people, and inventive student groups from more than 20 countries, who made this event a great success. The conference brought together many subfields of neurodegenerative disorders with plenary speeches and seminars given by guests from various institutions and organisations.

In response to Parkinsons 2022, we are excited to extend an invitation to you to attend our upcoming 9th International Conference on Parkinson's and Movement Disorders, which will be held in Vienna, Austria, on October 02–04, 2023. In order to make this event a success once again, we look forward to seeing your participation and support.